Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zai LabZLAB -2.76%72 EV-to-Revenue is 5.78 as of Aug. 30, 2026, which is 50% below its 10-year median of 11.62. GuruFocus rates ZLAB with a GF Score™ of 72/100 and a GF Value™ of $28.53 (Fairly Valued). The stock has 8 warning signs investors should review. Among 960 Biotechnology companies, Zai Lab ranks better than 60.62% on this metric.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Zai Lab's enterprise value is $2,598.7 Mil.
Zai Lab's Revenue for the trailing twelve months (TTM) ended in Jun. 2026 was $449.6 Mil. Therefore, Zai Lab's EV-to-Revenue for today is 5.78.
The historical rank and industry rank for Zai Lab's EV-to-Revenue or its related term are showing as below:
ZLAB'
s EV-to-Revenue Range Over the Past 10 Years
Min: 2.69 Med: 11.62 Max: 14472.04
Current: 5.78
During the past 11 years, the highest EV-to-Revenue of Zai Lab was 14472.04. The lowest was 2.69. And the median was 11.62.
ZLAB's EV-to-Revenue is ranked better than 60.62% of 960
companies
in the Biotechnology industry
Industry Median: 8.725
vs ZLAB: 5.78
As of today (2026-08-30), Zai Lab's stock price is $26.089.
Zai Lab's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was $4.06. Therefore, Zai Lab's PS Ratio for today is 6.43.
Zai Lab's share price for today is $26.089.
Zai Lab's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.06.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zai Lab EV-to-Revenue Related Terms
Zai Lab EV-to-Revenue Historical Data
* Premium members only.
The historical data trend for Zai Lab's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Zai Lab's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zai Lab EV-to-Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zai Lab's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Zai Lab's EV-to-Revenue falls into.
Zai Lab's current Enterprise Value is $2,598.7 Mil.
Zai Lab's Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $449.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zai Lab (ZLAB) has a EV-to-Revenue of 5.78 as of Aug. 30, 2026. EV to Revenue ratio is the company's enterprise value divided by sales. View historical data on Zai Lab and its competitors. This is 50% below median its historical median of 11.62. Over the past decade, Zai Lab's EV-to-Revenue has ranged from 2.69 to 14,472.04. According to the industry distribution chart, Zai Lab ranks #378 out of 960 companies in the Biotechnology industry, placing it in the top 39.4%.
Is Zai Lab's EV-to-Revenue too high?
Zai Lab's current EV-to-Revenue of 5.78 is 50% below median its 10-year median of 11.62. Over the past 10 years, this metric has ranged from a low of 2.69 to a high of 14,472.04. The Biotechnology industry median EV-to-Revenue is 8.73. Zai Lab's value of 5.78 is 33.8% below this industry median. Based on the distribution chart, Zai Lab ranks #378 out of 960 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Zai Lab has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zai Lab's EV-to-Revenue compare to COAG and SLS?
According to the Biotechnology industry distribution chart, Zai Lab ranks #378 out of 960 companies for EV-to-Revenue. This puts Zai Lab in the upper half of its industry. The industry median EV-to-Revenue is 8.73. Zai Lab's value of 5.78 is 33.8% below this benchmark. Historically, Zai Lab's own EV-to-Revenue has ranged from 2.69 to 14,472.04 over the past decade. While the company's 10-year median is 11.62 vs. the industry median of 8.73, Zai Lab has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-Revenue for a Biotechnology company?
The median EV-to-Revenue among Biotechnology companies is 8.73, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-Revenue significantly above this median, while those in the bottom quartile fall well below. However, EV-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zai Lab's current EV-to-Revenue of 5.78 is 33.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-Revenue mean?
A high EV-to-Revenue can signal that a stock is expensive relative to its fundamentals. EV to Revenue ratio is the company's enterprise value divided by sales. View historical data on Zai Lab and its competitors. For the Biotechnology industry, the median EV-to-Revenue is 8.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zai Lab's current EV-to-Revenue is 5.78, which is 50% below median its own 10-year median of 11.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zai Lab stock overvalued right now?
Based on GuruFocus' analysis, Zai Lab (ZLAB) is currently considered Fairly Valued. The stock's GF Value™ is $28.53, compared to a current price of $26.09 — trading 8.6% below its estimated fair value. The current EV-to-Revenue is 5.78, which is 50% below median its 10-year median of 11.62 and 33.8% below the Biotechnology industry median of 8.73. Zai Lab's overall GF Score™ is 72/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-Revenue calculated?
EV-to-Revenue is calculated from a company's financial statements. For Zai Lab (ZLAB), the current EV-to-Revenue is 5.78 as of Aug. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zai Lab (ZLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Zai Lab stock appears to be undervalued.
The current stock price of $26.09 is trading 8.6% below its estimated GF Value™ of $28.53.
GuruFocus considers Zai Lab to be Fairly Valued.
Key valuation signals for ZLAB:
EV-to-Revenue: 5.78 (50% below median its 10-year median of 11.62)
GF Value™: $28.53 vs. price of $26.09 (8.6% below fair value)
Industry Position: 33.8% below the Biotechnology median (#378 of 960)
No single metric tells the full story. See the ZLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
72GF Score
Get the complete analysis for ZLAB
EV-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZLAB has been successfully added to your 
